Histogen Inc. Common Stock
HSTO
HSTO was delisted on the 4th of October, 2023.
9 hedge funds and large institutions have $9.53K invested in Histogen Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
31% less funds holding
Funds holding: 13 → 9 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
91% less capital invested
Capital invested by funds: $108K → $9.53K (-$98.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$62 |
| 2 |
Wells Fargo
San Francisco,
California
|
+$22 |
| 3 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$42.8K |
| 2 |
BlackRock
New York
|
-$24.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$7.46K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.59K |
HSTO Hedge Fund Activity: Q3 2023 in Review
9 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Histogen Inc. Common Stock (HSTO) for Q3 2023, worth a combined $9.53K — down 91% from $108K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HSTO and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, opening a new position worth an estimated $62. The largest seller was Vanguard Group, exiting entirely with an estimated $42.8K sold.
- 9 institutional investors held Histogen Inc. Common Stock (HSTO) as of Q3 2023, down from 13 in Q2 2023.
- Funds reported $9.53K of Histogen Inc. Common Stock stock for Q3 2023, down 91% quarter-over-quarter.
- 2 funds opened new Histogen Inc. Common Stock positions in Q3 2023 and 6 closed out, a net change of -4 holders.
- The largest Histogen Inc. Common Stock buyer in Q3 2023 was UBS Group, an estimated $62 added.
- The largest Histogen Inc. Common Stock seller in Q3 2023 was Vanguard Group, an estimated $42.8K sold.
Based on aggregated 13F filings for Q3 2023.